Immatics
Immatics is a biotechnology company founded in 2000 in Tübingen, Germany, that develops T-cell-based cancer immunotherapies. Its pipeline includes investigational cell therapies and bispecifics directed at PRAME and other cancer targets, supported by target-discovery and T-cell receptor technologies.
Key facts
| Also Known As | Immatics |
|---|---|
| Business Model | Licensing |
| Legal Name | Immatics N.V. |
| Company Operating Status | Active |
| Full Address | 2201 W. Holcombe Blvd., Suite 205, Houston, Texas 77030 |
| Ticker Symbol | IMTX |
| Wellfound ID | immatics-biotechnologies |
| Wikidata ID | Q30256960 |
Contact details
Email and phone for Immatics are available to signed-in members of CliffBio.
Sign in to view